文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Potential Mechanism Underlying the Role of Mitochondria in Breast Cancer Drug Resistance and Its Related Treatment Prospects.

作者信息

Li Yuefeng, Li Zhian

机构信息

Department of Oncological Surgery, Shaoxing Second Hospital, Shaoxing, China.

出版信息

Front Oncol. 2021 Mar 18;11:629614. doi: 10.3389/fonc.2021.629614. eCollection 2021.


DOI:10.3389/fonc.2021.629614
PMID:33816265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8013997/
Abstract

Breast cancer incidence and mortality rates have been consistently high among women. The use of diverse therapeutic strategies, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy, has improved breast cancer prognosis. However, drug resistance has become a tremendous obstacle in overcoming breast cancer recurrence and metastasis. It is known that mitochondria play an important role in carcinoma cell growth, invasion and apoptosis. Recent studies have explored the involvement of mitochondrial metabolism in breast cancer prognosis. Here, we will provide an overview of studies that investigated mitochondrial metabolism pathways in breast cancer treatment resistance, and discuss the application prospects of agents targeting mitochondrial pathways against drug-resistant breast cancer.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f7/8013997/17088cc6f1f9/fonc-11-629614-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f7/8013997/d8c94d4b5459/fonc-11-629614-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f7/8013997/17088cc6f1f9/fonc-11-629614-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f7/8013997/d8c94d4b5459/fonc-11-629614-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72f7/8013997/17088cc6f1f9/fonc-11-629614-g002.jpg

相似文献

[1]
Potential Mechanism Underlying the Role of Mitochondria in Breast Cancer Drug Resistance and Its Related Treatment Prospects.

Front Oncol. 2021-3-18

[2]
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.

J Hematol Oncol. 2022-7-18

[3]
Mitochondria and cancer chemoresistance.

Biochim Biophys Acta Bioenerg. 2017-2-1

[4]
Overview of resistance to systemic therapy in patients with breast cancer.

Adv Exp Med Biol. 2007

[5]
Mitochondrial transplantation regulates antitumour activity, chemoresistance and mitochondrial dynamics in breast cancer.

J Exp Clin Cancer Res. 2019-1-23

[6]
Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.

Oncotarget. 2017-3-2

[7]
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.

Drug Resist Updat. 2017-8-19

[8]
Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer.

Cancers (Basel). 2023-3-23

[9]
The Role of MicroRNAs in the Chemoresistance of Breast Cancer.

Drug Dev Res. 2015-11

[10]
Drug uptake-based chemoresistance in breast cancer treatment.

Biochem Pharmacol. 2020-4-7

引用本文的文献

[1]
Metabolomics in Breast Cancer: From Biomarker Discovery to Personalized Medicine.

Metabolites. 2025-6-23

[2]
Ultrasound genomics related mitochondrial gene signature for prognosis and neoadjuvant chemotherapy resistance in triple negative breast cancer.

Oncol Res. 2025-2-28

[3]
Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application.

Front Pharmacol. 2025-1-10

[4]
Mitochondria-localized MBD2c facilitates mtDNA transcription and drug resistance.

Nat Chem Biol. 2025-6

[5]
A Nanorobotics-Based Approach of Breast Cancer in the Nanotechnology Era.

Int J Mol Sci. 2024-5-2

[6]
An ULK1/2-PXN mechanotransduction pathway suppresses breast cancer cell migration.

EMBO Rep. 2023-11-6

[7]
Roles of Mitochondria in Oral Squamous Cell Carcinoma Therapy: Friend or Foe?

Cancers (Basel). 2022-11-22

[8]
The Anti-Breast Cancer Activity of Dihydroartemisinin-5-methylisatin Hybrids Tethered via Different Carbon Spacers.

Molecules. 2022-11-18

[9]
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis.

Cancer Res Commun. 2022-10-10

[10]
Eupalinolide O Induces Apoptosis in Human Triple-Negative Breast Cancer Cells via Modulating ROS Generation and Akt/p38 MAPK Signaling Pathway.

J Oncol. 2022-9-21

本文引用的文献

[1]
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.

Breast Cancer Res. 2020-11-30

[2]
Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells.

Cancers (Basel). 2020-9-8

[3]
Antitumor Actions of Intratumoral Delivery of Membrane-Fused Mitochondria in a Mouse Model of Triple-Negative Breast Cancers.

Onco Targets Ther. 2020-6-9

[4]
Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells.

Antioxidants (Basel). 2020-4-16

[5]
Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.

ACS Nano. 2020-3-24

[6]
pH-sensitive pluronic micelles combined with oxidative stress amplification for enhancing multidrug resistance breast cancer therapy.

J Colloid Interface Sci. 2020-1-14

[7]
Recent treatment progress of triple negative breast cancer.

Prog Biophys Mol Biol. 2020-3

[8]
MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer.

Cancer Res. 2019-10-3

[9]
MCL-1 inhibitors - where are we now (2019)?

Expert Opin Ther Pat. 2019-10-14

[10]
Mitochondrial fragmentation, elevated mitochondrial superoxide and respiratory supercomplexes disassembly is connected with the tamoxifen-resistant phenotype of breast cancer cells.

Free Radic Biol Med. 2019-9-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索